About the 14th World ADC London 2024

Europe's Longest Standing & Definitive Antibody-Drug Conjugate Event

Unearth In-Depth Insights to Supercharge Your ADC Pipeline & Unleash Its Full Therapeutic Potential for Cutting-Edge Front-Line Treatment

Antibody-drug conjugates are the moment now, with the past year celebrating new approvals, positive clinical data, and over 300 ADCs in various stages of clinical development promising a bright future for these therapies in the fight against cancer.

As the field enters a new era with pipelines continuing to expand for 2024 and beyond, the 14th World ADC London was your opportunity to reflect on the drivers of success behind the superstar drugs ENHERTU and ELAHARE, discuss exciting novel approaches to drug-conjugate design, finetune translation, understand novel mechanisms of action, combat off-target toxicities and streamline manufacturing processes.

Confirmed attendees so far include Daiichi Sankyo, AstraZeneca, Seagen, Immunogen, Gilead, and many more.

No matter what stage of development you're focusing on, this was a one-stop shop for antibody-drug conjugates from early-stage discovery through to manufacturing and commercialisation

World ADC London Banner (1)

Hear What Previous Attendees have Said:

"Great experience! I really enjoyed the talks and the panel discussions covering different areas of expertise which matter for ADC development"
Heidelberg Pharma

Screenshot 2023-10-02 143321
Screenshot 2023-10-02 142237

"World ADC London is the number one ADC meeting in Europe"
Pierre Fabre Group

"This is the greatest ADC conference, we have an excellent update on all aspects of ADCs and innovation across the globe"
Innate Pharma

Screenshot 2023-10-02 143003